TRIPEPI, GIOVANNI LUIGI
 Distribuzione geografica
Continente #
AS - Asia 571
NA - Nord America 310
EU - Europa 225
SA - Sud America 151
AF - Africa 18
OC - Oceania 1
Totale 1.276
Nazione #
US - Stati Uniti d'America 287
SG - Singapore 254
CN - Cina 121
BR - Brasile 118
IT - Italia 112
VN - Vietnam 83
HK - Hong Kong 39
DE - Germania 26
FI - Finlandia 19
KR - Corea 18
RU - Federazione Russa 17
GB - Regno Unito 12
AR - Argentina 11
BD - Bangladesh 11
FR - Francia 10
MX - Messico 10
UA - Ucraina 8
CA - Canada 7
EC - Ecuador 7
PK - Pakistan 7
ID - Indonesia 5
NL - Olanda 5
PY - Paraguay 5
TR - Turchia 5
VE - Venezuela 5
ZA - Sudafrica 5
AT - Austria 4
CZ - Repubblica Ceca 4
EG - Egitto 4
IN - India 4
IQ - Iraq 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
JP - Giappone 3
PA - Panama 3
SA - Arabia Saudita 3
JO - Giordania 2
KE - Kenya 2
KZ - Kazakistan 2
RO - Romania 2
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CH - Svizzera 1
CO - Colombia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GT - Guatemala 1
LB - Libano 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PS - Palestinian Territory 1
SN - Senegal 1
SY - Repubblica araba siriana 1
UZ - Uzbekistan 1
Totale 1.276
Città #
Singapore 92
Florence 74
Ashburn 47
Boardman 47
Hong Kong 39
Hefei 31
Dallas 30
Ho Chi Minh City 28
Beijing 27
Seoul 18
Munich 17
Shanghai 16
Los Angeles 13
Helsinki 11
Noto 11
Sesto Fiorentino 11
Hanoi 10
São Paulo 10
Washington 10
New York 7
Santa Clara 7
Turku 7
Brooklyn 6
Da Nang 5
Guayaquil 5
Belo Horizonte 4
Biên Hòa 4
Brasília 4
Haiphong 4
Montreal 4
Mexico City 3
Ninh Bình 3
Phoenix 3
Quảng Ngãi 3
Thái Nguyên 3
Tokyo 3
Vienna 3
Alexandria 2
Amman 2
Amsterdam 2
Ankara 2
Atlanta 2
Campinas 2
Can Tho 2
Casablanca 2
Caxias do Sul 2
Charlotte 2
Chicago 2
Falkenstein 2
Feira de Santana 2
Guangzhou 2
Jinhua 2
Juiz de Fora 2
Jundiaí 2
Kyiv 2
London 2
Milan 2
Mosul 2
Mumbai 2
Nairobi 2
Ogden 2
Olomouc 2
Quito 2
Rio de Janeiro 2
Roubaix 2
San Francisco 2
Secaucus 2
Sorocaba 2
Três Lagoas 2
Wuhan 2
Addis Ababa 1
Ajman 1
Al Qaţīf 1
Almaty 1
Antalya 1
Aracati 1
Aragarças 1
Araraquara 1
Araçuaí 1
Astana 1
Asunción 1
Auckland 1
Bakersfield 1
Baku 1
Bandar Seri Begawan 1
Barranqueras 1
Barueri 1
Bauru 1
Beirut 1
Blitar 1
Blumenau 1
Boston 1
Brownsville 1
Bucharest 1
Buon Ma Thuot 1
Bursa 1
Bắc Giang 1
Cabreúva 1
Cairo 1
Cajamar 1
Totale 716
Nome #
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 91
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 90
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 89
Genes selection using deep learning and explainable artificial intelligence for chronic lymphocytic leukemia predicting the need and time to therapy 89
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 84
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 81
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 80
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 79
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 76
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 75
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 73
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 73
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 71
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 65
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 63
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 60
Long-term cognitive function changes with non-vitamin K oral anticoagulants in older patients with atrial fibrillation. A multicenter cohort study 55
Totale 1.294
Categoria #
all - tutte 7.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.745


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202328 0 0 0 0 0 0 14 0 0 3 11 0
2023/2024239 3 8 52 46 29 32 14 4 4 2 4 41
2024/2025399 9 32 8 25 24 24 8 12 70 41 40 106
2025/2026628 133 66 83 74 197 75 0 0 0 0 0 0
Totale 1.294